180 related articles for article (PubMed ID: 30194584)
21. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
22. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.
Chen W; Ward T; Tan MP; Yan J; Wang PF; Wygant GD; Gordon J
J Comp Eff Res; 2018 Aug; 7(8):785-795. PubMed ID: 29860879
[No Abstract] [Full Text] [Related]
23. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
Chen P; Jin M; Cao Y; Li H
Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
Tsai TC; Deng ST; Hsu CW
J Med Virol; 2020 Feb; 92(2):219-226. PubMed ID: 31599455
[TBL] [Abstract][Full Text] [Related]
25. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
26. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Yoneyama H; Morishita A; Iwama H; Fujita K; Masaki T; Tani J; Tadokoro T; Nomura T; Sakamoto T; Oura K; Takuma K; Nakahara M; Mimura S; Deguchi A; Oryu M; Tsutsui K; Himoto T; Shimotohno K; Wakita T; Kobara H; Masaki T
J Gastroenterol Hepatol; 2021 Apr; 36(4):1126-1135. PubMed ID: 32839985
[TBL] [Abstract][Full Text] [Related]
27. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Foster GR; Agarwal K; Cramp ME; Moreea S; Barclay S; Collier J; Brown AS; Ryder SD; Ustianowski A; Forton DM; Fox R; Gordon F; Rosenberg WM; Mutimer DJ; Du J; Gilbert CL; Asante-Appiah E; Wahl J; Robertson MN; Barr E; Haber B
Hepatology; 2018 Jun; 67(6):2113-2126. PubMed ID: 29473975
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
Wang HL; Lu X; Yang X; Xu N
J Gastroenterol Hepatol; 2017 Jan; 32(1):45-52. PubMed ID: 27597318
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Choi DT; Puenpatom A; Yu X; Erickson KF; Kanwal F; El-Serag HB; Kramer JR
Antiviral Res; 2020 Feb; 174():104698. PubMed ID: 31862503
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
Hernández-Conde M; Fernández I; Perelló C; Gallego A; Bonacci M; Pascasio JM; Romero-Gómez M; Llerena S; Fernández-Rodríguez C; Castro Urda JL; García Buey L; Carmona I; Morillas RM; García ND; Gea F; Carrión JA; Castellote J; Moreno-Planas JM; Piqueras Alcol B; Molina E; Diago M; Montoliu S; de la Vega J; Menéndez F; Sánchez Ruano JJ; García-Samaniego J; Rosales-Zabal JM; Anton MD; Badia E; Souto-Rodríguez R; Salmeron FJ; Fernández-Bermejo M; Figueruela B; Moreno-Palomares JJ; Calleja JL
J Viral Hepat; 2019 Jan; 26(1):55-64. PubMed ID: 30265418
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
[TBL] [Abstract][Full Text] [Related]
32. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Kao JH; Jensen DM; Manns MP; Jacobson I; Kumada H; Toyota J; Heo J; Yoffe B; Sievert W; Bessone F; Peng CY; Roberts SK; Lee YJ; Bhore R; Mendez P; Hughes E; Noviello S
Liver Int; 2016 Jul; 36(7):954-62. PubMed ID: 26683763
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
[No Abstract] [Full Text] [Related]
35. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
[TBL] [Abstract][Full Text] [Related]
36. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
Kramer JR; Puenpatom A; Erickson KF; Cao Y; Smith D; El-Serag HB; Kanwal F
J Viral Hepat; 2018 Nov; 25(11):1270-1279. PubMed ID: 29851265
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S1-S8. PubMed ID: 32539296
[TBL] [Abstract][Full Text] [Related]
40. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
